We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sample Collection in PPTs Affects HIV-Load Testing

By LabMedica International staff writers
Posted on 14 Jul 2009
Use of plasma preparation tubes (PPTs) for sample collection in patients with human immunodeficiency virus 1 (HIV-1) could affect the results of viral RNA load testing.

HIV-1 load is an important marker of disease progression and treatment efficacy in patients with HIV-1 infection. More...
An increase in the number of samples with detectable HIV-1 RNA has been reported among patients with previously suppressed viral loads.

Scientists studied whether the overestimation of HIV-1 RNA was due to the presence of cells in plasma from plasma preparation tubes. Anne-Marte Bakken Kran and colleagues, at the department of microbiology, national reference laboratory for HIV, Oslo University Hospital (Ulleval, Norway), carried out the investigation. They demonstrated that HIV-1 RNA levels in plasma collected in PPTs that had been centrifuged before being transported to the laboratory were elevated compared with those collected in PPTs that had been centrifuged after arrival in the laboratory.

In addition, plasma from the PPTs that had been centrifuged before transport to the laboratory also contained cell-associated HIV-1 nucleic acids and abundant blood cells, a finding not observed with PPTs that were centrifuged after

The authors concluded that transportation of PPTs after centrifugation could cause release of cells in the plasma fraction containing cell-associated HIV-1 nucleic acids. These cells contributed significantly to the HIV-1 RNA copy numbers in patients with low viral loads.

The study was published in the July 2009 edition of the Journal of Clinical Microbiology.

Related Links:

Oslo University Hospital



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.